论文部分内容阅读
目的:探究培美曲塞+顺铂方案诱导化疗联合同期放化疗对局部晚期非小细胞肺癌的近期疗效及安全性。方法:收集我院肿瘤科2009年7月到2011年7月住院治疗的局部晚期非鳞癌非小细胞癌患者54例,按照随机数字表法分为研究组和对照组,每组27例,研究组给予培美曲塞+顺铂方案诱导化疗联合同期放化疗,对照组仅给予培美曲塞+顺铂方案化疗联合同期放疗,治疗2个周期,随访2年,对比两组患者的近期疗效及安全性。结果:研究组的近期有效率和控制率分别为55.56%、77.78%,高于对照组的50.33%和59.26%,有效率和控制率差异具有统计学意义(P<0.05)。随访2年,研究组的中位生存期为12.77个月,1年生存率为48.15%,高于对照组中位生存期11.28个月,1年生存率40.74%,但差异无统计学意义(P>0.05),研究组2年生存率为43.46%,高于对照组的25.38%,差异具有统计学意义(P<0.05);研究组白细胞减少以及脱发发生率分别为37.0%、25.9%,低于对照组的81.5%和55.5%,差异具有统计学意义(均P<0.05);研究组中血小板减少、血红蛋白减少、呕吐、肝功能损害、肾功能损耗、皮疹等发生率分别为40.7%、22.2%、59.2%、11.1%、7.4%、14.8%,高于对照组中各不良反应发生率分别为33.3%、18.5%、55.5%、14.8%、11.1%、7.4%,但两组间差异无统计学意义(P>0.05)。结论:培美曲塞+顺铂方案诱导化疗联合同期放化疗对局部晚期非小细胞肺癌治疗效果明显,且不良反应少,可作为临床上晚期非小细胞肺癌化疗一线药物。
Objective: To investigate the short-term efficacy and safety of pemetrexed + cisplatin-induced chemotherapy plus concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. Methods: Totally 54 patients with locally advanced NSCLC who were hospitalized in our hospital from July 2009 to July 2011 were divided into study group and control group according to the random number table method, with 27 cases in each group. The study group was given pemetrexed + cisplatin chemotherapy induction chemotherapy combined with the same period, the control group was given pemetrexed + cisplatin chemotherapy alone with concurrent radiotherapy, the treatment of two cycles, followed up for 2 years, compared the two groups of patients with recent Efficacy and safety. Results: The effective rate and control rate of the study group were 55.56% and 77.78% respectively, higher than that of the control group (50.33% and 59.26%, P <0.05). The follow-up of 2 years, the study group’s median survival was 12.77 months, 1-year survival rate was 48.15%, higher than the median survival time of 11.28 months, 1-year survival rate was 40.74%, but the difference was not statistically significant P> 0.05). The 2-year survival rate was 43.46% in the study group, which was significantly higher than that in the control group (25.38%, P <0.05). The incidences of leukopenia and hair loss in the study group were 37.0% and 25.9% (P <0.05). The incidences of thrombocytopenia, hemoglobin decrease, vomiting, liver damage, renal dysfunction and skin rashes in the study group were 40.7% , 22.2%, 59.2%, 11.1%, 7.4% and 14.8% respectively, which were higher than those in the control group (33.3%, 18.5%, 55.5%, 14.8%, 11.1% and 7.4% The difference was not statistically significant (P> 0.05). Conclusion: Pemetrexed + cisplatin chemotherapy combined with concurrent chemoradiotherapy is effective in the treatment of locally advanced non-small cell lung cancer and has few side effects. It can be used as the first-line chemotherapy in advanced non-small cell lung cancer.